AR002976A1 - Formulaciones farmaceuticas parenterales de efecto prolongado de insulina; cristales de dichos analogos aplicables en dichas formulaciones yprocedimiento de las formulaciones mencionadas - Google Patents
Formulaciones farmaceuticas parenterales de efecto prolongado de insulina; cristales de dichos analogos aplicables en dichas formulaciones yprocedimiento de las formulaciones mencionadasInfo
- Publication number
- AR002976A1 AR002976A1 ARP960101937A AR10193796A AR002976A1 AR 002976 A1 AR002976 A1 AR 002976A1 AR P960101937 A ARP960101937 A AR P960101937A AR 10193796 A AR10193796 A AR 10193796A AR 002976 A1 AR002976 A1 AR 002976A1
- Authority
- AR
- Argentina
- Prior art keywords
- formulations
- insulin
- approximately
- long
- crystals
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Abstract
Se trata de formulaciones parenterales farmacéuticas de efecto prolongado, que comprenden: una suspensión acuosa estéril de aproximadamente 20 U/ml a 500U/ml de un análogo de insulina, aproximadamente 5 mg/ml a aproximadamente 10 mg /ml de cloruros ódico, aproximadamente 0,2 a 2,0 mg/ml de un tampónfisiológicamente aceptable, que contiene aproximadamente de 0,07-0,1 mg/ml de iones zinc y un conservante fisiológicamente aceptable, a un pH del orden de6,5 a 7,8; de modo que al menos 5% delanál ogo presente en la suspensión está disuelto. También se proponen los análogos de insulina cristalizados,utilizables en dichas formulaciones y la preparación de dichos análogos cristalizados.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41488095A | 1995-03-31 | 1995-03-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR002976A1 true AR002976A1 (es) | 1998-05-27 |
Family
ID=23643384
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP960101937A AR002976A1 (es) | 1995-03-31 | 1996-03-27 | Formulaciones farmaceuticas parenterales de efecto prolongado de insulina; cristales de dichos analogos aplicables en dichas formulaciones yprocedimiento de las formulaciones mencionadas |
Country Status (23)
Country | Link |
---|---|
US (1) | US5952297A (es) |
EP (1) | EP0735048A1 (es) |
JP (1) | JPH11502856A (es) |
KR (1) | KR19980703425A (es) |
CN (1) | CN1185114A (es) |
AR (1) | AR002976A1 (es) |
AU (1) | AU720300B2 (es) |
BR (1) | BR9607935A (es) |
CA (1) | CA2216516A1 (es) |
CO (1) | CO4700482A1 (es) |
CZ (1) | CZ305297A3 (es) |
EA (1) | EA000970B1 (es) |
HU (1) | HUP9801700A3 (es) |
IL (1) | IL117696A (es) |
MX (1) | MX9707428A (es) |
NO (1) | NO974498L (es) |
NZ (1) | NZ305719A (es) |
PE (1) | PE38797A1 (es) |
PL (1) | PL322626A1 (es) |
TR (1) | TR199701078T1 (es) |
WO (1) | WO1996030040A1 (es) |
YU (1) | YU18596A (es) |
ZA (1) | ZA962502B (es) |
Families Citing this family (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA984697B (en) * | 1997-06-13 | 1999-12-01 | Lilly Co Eli | Stable insulin formulations. |
SI0884053T1 (en) * | 1997-06-13 | 2003-02-28 | Eli Lilly And Company | Stable insulin formulations |
US20010007853A1 (en) * | 1998-01-08 | 2001-07-12 | Dimarchi Richard Dennis | Method for administering monomeric insulin analogs |
WO1999048520A1 (en) * | 1998-03-24 | 1999-09-30 | Joergensen Klavs Holger | Novel preparation of protracted acting human insulin |
US6211144B1 (en) * | 1998-10-16 | 2001-04-03 | Novo Nordisk A/S | Stable concentrated insulin preparations for pulmonary delivery |
US7169889B1 (en) * | 1999-06-19 | 2007-01-30 | Biocon Limited | Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin |
CN1125081C (zh) | 1999-09-08 | 2003-10-22 | 中国科学院上海生物化学研究所 | 重组天然和新型人胰岛素及其制备方法 |
AU2001220765A1 (en) | 2000-01-24 | 2001-07-31 | Medtronic Minimed, Inc. | Mixed buffer system for stabilizing polypeptide formulations |
EP1346726A4 (en) * | 2000-12-25 | 2004-09-15 | Shiseido Co Ltd | FRAGRANCE COMPOSITION STIMULATING THE SYMPATHETIC SYSTEM |
HUP0500733A3 (en) * | 2001-02-09 | 2010-01-28 | Genentech Inc | Crystallization of igf-1 |
US6828297B2 (en) | 2001-06-04 | 2004-12-07 | Nobex Corporation | Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
US7713932B2 (en) | 2001-06-04 | 2010-05-11 | Biocon Limited | Calcitonin drug-oligomer conjugates, and uses thereof |
US6828305B2 (en) | 2001-06-04 | 2004-12-07 | Nobex Corporation | Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
US6713452B2 (en) | 2001-06-04 | 2004-03-30 | Nobex Corporation | Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
US6737401B2 (en) | 2001-06-28 | 2004-05-18 | Metronic Minimed, Inc. | Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom |
US7030082B2 (en) * | 2001-09-07 | 2006-04-18 | Nobex Corporation | Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith |
US6913903B2 (en) * | 2001-09-07 | 2005-07-05 | Nobex Corporation | Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same |
US7312192B2 (en) * | 2001-09-07 | 2007-12-25 | Biocon Limited | Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same |
US7166571B2 (en) * | 2001-09-07 | 2007-01-23 | Biocon Limited | Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same |
US6770625B2 (en) | 2001-09-07 | 2004-08-03 | Nobex Corporation | Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith |
US7683029B2 (en) * | 2003-05-07 | 2010-03-23 | Philip Morris Usa Inc. | Liquid aerosol formulations containing insulin and aerosol generating devices and methods for generating aerosolized insulin |
DK2626368T3 (en) | 2004-07-19 | 2017-02-27 | Biocon Ltd | INSULIN OLIGOMS CONJUGATES, FORMULATIONS AND APPLICATIONS THEREOF |
US7597884B2 (en) | 2004-08-09 | 2009-10-06 | Alios Biopharma, Inc. | Hyperglycosylated polypeptide variants and methods of use |
US7833513B2 (en) | 2004-12-03 | 2010-11-16 | Rhode Island Hospital | Treatment of Alzheimer's Disease |
WO2007121318A2 (en) | 2006-04-12 | 2007-10-25 | Emisphere Technologies, Inc. | Formulations for delivering insulin |
JP5868594B2 (ja) | 2007-10-16 | 2016-02-24 | バイオコン・リミテッドBiocon Limited | 経口投与可能な固形医薬組成物及びそのプロセス |
EP2231191A2 (en) * | 2007-12-11 | 2010-09-29 | ConjuChem Biotechnologies Inc. | Formulation of insulinotropic peptide conjugates |
EP2077132A1 (en) | 2008-01-02 | 2009-07-08 | Boehringer Ingelheim Pharma GmbH & Co. KG | Dispensing device, storage device and method for dispensing a formulation |
RU2524423C2 (ru) | 2008-01-09 | 2014-07-27 | Санофи-Авентис Дойчланд Гмбх | Новые производные инсулина с чрезвычайно замедленным профилем время/действие |
JP2012502048A (ja) | 2008-09-08 | 2012-01-26 | ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ | アルデヒドデヒドロゲナーゼ活性のモジュレーターおよびその使用方法 |
LT3228320T (lt) | 2008-10-17 | 2020-03-10 | Sanofi-Aventis Deutschland Gmbh | Insulino ir glp-1 agonisto derinys |
KR20110082180A (ko) | 2008-10-28 | 2011-07-18 | 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 | 알데히드 탈수소효소의 조절자 및 그것의 사용방법 |
EP2391217A4 (en) | 2009-01-28 | 2015-05-20 | Smartcells Inc | SYNTHETIC CONJUGATES AND USES THEREOF |
NZ594248A (en) | 2009-01-28 | 2015-03-27 | Smartcells Inc | Conjugate based systems for controlled drug delivery |
WO2010092218A2 (es) | 2009-02-12 | 2010-08-19 | Proyecto De Biomedicina Cima, S.L. | Uso de la cardiotrofina-1 para el tratamiento de enfermedades metabólicas |
AU2010226243A1 (en) | 2009-03-20 | 2011-09-22 | Smartcells, Inc. | Terminally-functionalized conjugates and uses thereof |
WO2010112358A2 (de) | 2009-03-31 | 2010-10-07 | Boehringer Ingelheim International Gmbh | Verfahren zur beschichtung einer oberfläche eines bauteils |
EP3508239B1 (de) | 2009-05-18 | 2020-12-23 | Boehringer Ingelheim International GmbH | Adapter, inhalationseinrichtung und zerstäuber |
BR112012011403B8 (pt) | 2009-11-13 | 2021-05-25 | Sanofi Aventis Deutschland | composição farmacêutica líquida compreendendo um agonista glp-1 e metionina e uso da mesma |
PL3417871T3 (pl) | 2009-11-13 | 2021-06-14 | Sanofi-Aventis Deutschland Gmbh | Kompozycja farmaceutyczna zawierająca agonistę GLP-1, insulinę i metioninę |
US10016568B2 (en) | 2009-11-25 | 2018-07-10 | Boehringer Ingelheim International Gmbh | Nebulizer |
EP2504051B1 (en) | 2009-11-25 | 2019-09-04 | Boehringer Ingelheim International GmbH | Nebulizer |
EP2504052B1 (en) | 2009-11-25 | 2022-07-27 | Boehringer Ingelheim International GmbH | Nebulizer |
AU2011202239C1 (en) * | 2010-05-19 | 2017-03-16 | Sanofi | Long-acting formulations of insulins |
JP5874724B2 (ja) | 2010-06-24 | 2016-03-02 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ネブライザ |
MX339614B (es) | 2010-08-30 | 2016-06-02 | Sanofi - Aventis Deutschland GmbH | Uso de ave0010 para la fabricacion de un medicamento para el tratamiento de la diabetes mellitus tipo 2. |
WO2012130757A1 (de) | 2011-04-01 | 2012-10-04 | Boehringer Ingelheim International Gmbh | Medizinisches gerät mit behälter |
US10457659B2 (en) | 2011-04-29 | 2019-10-29 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for increasing proliferation of adult salivary stem cells |
US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
US9827384B2 (en) | 2011-05-23 | 2017-11-28 | Boehringer Ingelheim International Gmbh | Nebulizer |
US9408893B2 (en) | 2011-08-29 | 2016-08-09 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for use in glycemic control in diabetes type 2 patients |
AR087744A1 (es) | 2011-09-01 | 2014-04-16 | Sanofi Aventis Deutschland | Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa |
WO2013152894A1 (de) | 2012-04-13 | 2013-10-17 | Boehringer Ingelheim International Gmbh | Zerstäuber mit kodiermitteln |
CA2890048C (en) | 2012-12-03 | 2022-05-03 | Merck Sharp & Dohme Corp. | O-glycosylated carboxy terminal portion (ctp) peptide-based insulin and insulin analogues |
US9670162B2 (en) | 2013-03-14 | 2017-06-06 | The Board Of Trustees Of The Leland Stanford Junio | Mitochondrial aldehyde dehyrogenase-2 modulators and methods of use thereof |
MX369511B (es) | 2013-04-03 | 2019-11-11 | Sanofi Sa | Tratamiento de la diabetes mellitus mediante formulaciones de insulinas de acción prolongada. |
JP6643231B2 (ja) | 2013-08-09 | 2020-02-12 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ネブライザ |
ES2836977T3 (es) | 2013-08-09 | 2021-06-28 | Boehringer Ingelheim Int | Nebulizador |
WO2015084694A2 (en) | 2013-12-04 | 2015-06-11 | Merck Sharp & Dohme Corp. | Method for preparing crystalline insulin |
DK3139984T3 (da) | 2014-05-07 | 2021-07-19 | Boehringer Ingelheim Int | Forstøver |
WO2015169732A1 (en) | 2014-05-07 | 2015-11-12 | Boehringer Ingelheim International Gmbh | Container, nebulizer and use |
HRP20220596T1 (hr) | 2014-05-07 | 2022-06-24 | Boehringer Ingelheim International Gmbh | Raspršivač |
BR112017000175B1 (pt) * | 2014-07-08 | 2023-11-21 | Amphastar Pharmaceuticals,Inc. | Método de preparação de uma insulina inalável adequada para a liberação pulmonar e partículas de insulina micronizadas |
WO2016032869A1 (en) | 2014-08-26 | 2016-03-03 | Merck Sharp & Dohme Corp. | Method for preparing crystalline insulin or insulin analog compositions |
ES2949095T3 (es) | 2014-12-12 | 2023-09-25 | Sanofi Aventis Deutschland | Formulación de relación fija de insulina glargina/lixisenatida |
TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第2型糖尿病病患治療 |
TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第2型糖尿病病患之治療 |
US10322168B2 (en) | 2016-01-07 | 2019-06-18 | Amphastar Pharmaceuticals, Inc. | High-purity inhalable particles of insulin and insulin analogues, and high-efficiency methods of manufacturing the same |
US11820805B2 (en) | 2017-12-18 | 2023-11-21 | Merck Sharp & Dohme Llc | Conjugate based systems for controlled insulin delivery |
WO2019125879A2 (en) | 2017-12-18 | 2019-06-27 | Merck Sharp & Dohme Corp. | Conjugate based systems for controlled insulin delivery |
JP2023520049A (ja) | 2020-03-31 | 2023-05-15 | プロトマー・テクノロジーズ・インコーポレイテッド | 隣接ジオールに対する選択的応答性のためのコンジュゲート |
TW202237188A (zh) | 2020-11-19 | 2022-10-01 | 美商普羅托莫科技公司 | 芳族含硼化合物及胰島素類似物 |
US20230374045A1 (en) | 2022-05-18 | 2023-11-23 | Protomer Technologies Inc. | Aromatic boron-containing compounds and related insulin analogs |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2626228A (en) * | 1945-05-17 | 1953-01-20 | Novo Terapeutisk Labor As | Method of producing crystalline insulin |
US2882202A (en) * | 1950-04-05 | 1959-04-14 | Novo Terapeutisk Labor As | Insulin crystal preparations and methods of producing them |
US2648622A (en) * | 1950-11-29 | 1953-08-11 | Research Corp | Purifying insulin by seeding with unclumped fibrils of insulin |
US2882203A (en) * | 1951-06-26 | 1959-04-14 | Novo Terapeutisk Labor As | Injectable insulin preparation with protracted effect |
DK78069C (da) * | 1952-06-23 | 1954-09-06 | Novo Terapeutisk Labor As | Fremgangsmåde til fremstilling af krystallinsk insulin. |
US2849370A (en) * | 1953-06-04 | 1958-08-26 | Novo Terapeutisk Labortorium A | Injectable insulin preparations with protracted effect and process of producing same |
US3102077A (en) * | 1953-08-19 | 1963-08-27 | Christensen Henry Marinus | Preparation of insulin containing 2.75 to 8 percent zinc content |
US2819999A (en) * | 1953-11-13 | 1958-01-14 | Novo Terapeutisk Labor As | Process for crystallization of insulin using freeze dried insulin as seeding material |
US2799622A (en) * | 1953-11-14 | 1957-07-16 | Novo Terapeutisk Labor As | Process of producing insulin crystals of substantially uniform size and compositions thereof |
US3060093A (en) * | 1957-07-18 | 1962-10-23 | Nordisk Insulinlab | Slowly acting insulin preparation in crystalline form and method of preparation |
AT304760B (de) * | 1969-08-08 | 1973-01-25 | Novo Terapeutisk Labor As | Verfahren zur Reinigung von Insulin |
DE2933946A1 (de) * | 1979-08-22 | 1981-03-12 | Hoechst Ag, 6000 Frankfurt | Insulinkristallsuspension und verfahren zu ihrer herstellung. |
FI78616C (fi) * | 1982-02-05 | 1989-09-11 | Novo Industri As | Foerfarande foer framstaellning av en foer infusionsaendamaol avsedd stabiliserad insulinloesning, som har en foerhoejd zinkhalt. |
DE3327709A1 (de) * | 1983-07-29 | 1985-02-07 | Hoechst Ag, 6230 Frankfurt | Insulin-derivat-kristallsuspensionen, verfahren zu deren herstellung und deren verwendung |
PH25772A (en) * | 1985-08-30 | 1991-10-18 | Novo Industri As | Insulin analogues, process for their preparation |
PH23446A (en) * | 1986-10-20 | 1989-08-07 | Novo Industri As | Peptide preparations |
DE3827533A1 (de) * | 1988-08-13 | 1990-02-15 | Hoechst Ag | Pharmazeutische zubereitung zur behandlung des diabetes mellitus |
US5514646A (en) * | 1989-02-09 | 1996-05-07 | Chance; Ronald E. | Insulin analogs modified at position 29 of the B chain |
US5534488A (en) * | 1993-08-13 | 1996-07-09 | Eli Lilly And Company | Insulin formulation |
AU711428B2 (en) * | 1994-06-16 | 1999-10-14 | Eli Lilly And Company | Monomeric insulin analog formulations |
US5461031A (en) * | 1994-06-16 | 1995-10-24 | Eli Lilly And Company | Monomeric insulin analog formulations |
US5474978A (en) * | 1994-06-16 | 1995-12-12 | Eli Lilly And Company | Insulin analog formulations |
US5504188A (en) * | 1994-06-16 | 1996-04-02 | Eli Lilly And Company | Preparation of stable zinc insulin analog crystals |
-
1996
- 1996-03-27 YU YU18596A patent/YU18596A/sh unknown
- 1996-03-27 AR ARP960101937A patent/AR002976A1/es not_active Application Discontinuation
- 1996-03-28 NZ NZ305719A patent/NZ305719A/en unknown
- 1996-03-28 CZ CZ973052A patent/CZ305297A3/cs unknown
- 1996-03-28 EA EA199700285A patent/EA000970B1/ru not_active IP Right Cessation
- 1996-03-28 PE PE1996000217A patent/PE38797A1/es not_active Application Discontinuation
- 1996-03-28 MX MX9707428A patent/MX9707428A/es unknown
- 1996-03-28 PL PL96322626A patent/PL322626A1/xx unknown
- 1996-03-28 KR KR1019970706829A patent/KR19980703425A/ko not_active Application Discontinuation
- 1996-03-28 HU HU9801700A patent/HUP9801700A3/hu unknown
- 1996-03-28 EP EP96302171A patent/EP0735048A1/en not_active Withdrawn
- 1996-03-28 JP JP8529728A patent/JPH11502856A/ja active Pending
- 1996-03-28 WO PCT/US1996/004424 patent/WO1996030040A1/en not_active Application Discontinuation
- 1996-03-28 TR TR97/01078T patent/TR199701078T1/xx unknown
- 1996-03-28 ZA ZA9602502A patent/ZA962502B/xx unknown
- 1996-03-28 CO CO96015449A patent/CO4700482A1/es unknown
- 1996-03-28 IL IL11769696A patent/IL117696A/xx not_active IP Right Cessation
- 1996-03-28 CA CA002216516A patent/CA2216516A1/en not_active Abandoned
- 1996-03-28 CN CN96194052A patent/CN1185114A/zh active Pending
- 1996-03-28 BR BR9607935A patent/BR9607935A/pt not_active Application Discontinuation
- 1996-03-28 AU AU53812/96A patent/AU720300B2/en not_active Ceased
-
1997
- 1997-09-26 US US08/938,245 patent/US5952297A/en not_active Expired - Fee Related
- 1997-09-29 NO NO974498A patent/NO974498L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
NZ305719A (en) | 1998-09-24 |
PE38797A1 (es) | 1997-10-04 |
US5952297A (en) | 1999-09-14 |
CO4700482A1 (es) | 1998-12-29 |
CA2216516A1 (en) | 1996-10-03 |
YU18596A (sh) | 1998-07-10 |
KR19980703425A (ko) | 1998-11-05 |
IL117696A (en) | 2000-01-31 |
PL322626A1 (en) | 1998-02-02 |
CN1185114A (zh) | 1998-06-17 |
HUP9801700A3 (en) | 1998-12-28 |
BR9607935A (pt) | 1998-06-02 |
AU5381296A (en) | 1996-10-16 |
TR199701078T1 (xx) | 1998-01-21 |
NO974498L (no) | 1997-10-08 |
HUP9801700A2 (hu) | 1998-11-30 |
EA199700285A1 (ru) | 1998-02-26 |
ZA962502B (en) | 1997-09-29 |
MX9707428A (es) | 1997-12-31 |
IL117696A0 (en) | 1996-07-23 |
CZ305297A3 (cs) | 1998-02-18 |
EA000970B1 (ru) | 2000-08-28 |
WO1996030040A1 (en) | 1996-10-03 |
JPH11502856A (ja) | 1999-03-09 |
NO974498D0 (no) | 1997-09-29 |
AU720300B2 (en) | 2000-05-25 |
EP0735048A1 (en) | 1996-10-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR002976A1 (es) | Formulaciones farmaceuticas parenterales de efecto prolongado de insulina; cristales de dichos analogos aplicables en dichas formulaciones yprocedimiento de las formulaciones mencionadas | |
AU599792B2 (en) | Anti-parkinsonian indolone derivatives | |
ES2107427T3 (es) | Aislamiento de aminoarginina y su uso para bloquear la formacion de oxido nitrico en el cuerpo. | |
TR200101049T2 (tr) | Siklik tetrapeptid bileşiği ve kullanımı | |
ATE58292T1 (de) | L-dopa enthaltendes arzneimittel. | |
SE8406538D0 (sv) | Novel derivatives of purine | |
BR9708706B8 (pt) | composição farmacêutica para administração intravenosa a um paciente | |
HUT70531A (en) | Arylmorpholine derivatives, pharmaceutical compositions containing them as active agent and process for preparing them | |
MY129946A (en) | Compound with gastric acid inhibitory effect and process for its preparation. | |
MY102662A (en) | Parenteral suspensions | |
IL103799A (en) | Fish production | |
FI913909A0 (fi) | t-PA pro:n stabilointi | |
US5093348A (en) | Pharmaceutical composition for topical ophthalmic use having improved local tolerability | |
PT98538A (pt) | Processo de preparacao de factor de crescimento humano epidermico (hegf) dos seus congeneres e de composicoes farmaceuticas que os contem | |
NO163133C (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktiv 5r, 6s, 8r-6-(1-hydroxyethyl)-2-(2-carbamoyloxy-ethylthio)-penem-3-carboxylsyre. | |
US4268518A (en) | Method of treating cystitis | |
HU896426D0 (en) | Process for the preparation of aquous solutions of doxorubicin | |
CA2022323A1 (en) | Excretion of potassium ion by prostanoic acid derivatives | |
IT1273628B (it) | Composizioni farmaceutiche per la cura della talassemia contenenti derivati dell'acido butirrico e in particolare isobutirramide | |
JO1231B1 (en) | A way to treat monocytes | |
JPS6425728A (en) | Nootropic (noesis improving agent) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |